BCAL Diagnostics

BCAL Diagnostics FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of BCAL Diagnostics (BDX.AX) as of Oct 17, 2026 is 95.62 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 88.66 % — a change of 7.85% (higher).

FCF Conversion

95.62 %

YoY

7.85%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of BCAL Diagnostics is 2025 95.62 % . FCF Conversion Rate (FCF/EBITDA) of BCAL Diagnostics was 2024 88.66 % . It decreases by 7.85% higher compared to the previous year.

The BCAL Diagnostics FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
103.68 AUD
Jan 1, 2019
123.84 AUD
Jan 1, 2020
95.56 AUD
Jan 1, 2021
79.36 AUD
Jan 1, 2022
95.85 AUD
Jan 1, 2023
126.65 AUD
Jan 1, 2024
88.66 AUD
Jan 1, 2025
95.62 AUD
The BCAL Diagnostics FCF Conversion history
YEARFCF ConversionYoY
95.62 %+7.85%
88.66 %-30.00%
126.65 %+32.13%
95.85 %+20.78%
79.36 %-16.95%
95.56 %-22.83%
123.84 %+19.44%
103.68 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

BCAL Diagnostics Stock analysis

What does BCAL Diagnostics do? BCAL Diagnostics Ltd, based in Sydney, Australia, operates in the Health Care sector within the Biotechnology industry. The company develops innovative blood screening tests for early breast cancer detection, focusing on a lipid biomarker-based approach known as the BCAL test. This technology complements existing imaging methods like mammograms and aims to support screening and monitoring for women of all ages and backgrounds. BCAL Diagnostics has partnered with Precion Inc. to advance clinical trials and regulatory approvals for its diagnostic solutions. BCAL Diagnostics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BCAL Diagnostics stock

FCF Conversion Rate (FCF/EBITDA) of BCAL Diagnostics is 95.62 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of BCAL Diagnostics changed from 88.66 % to 95.62 %, representing a 7.85% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) BCAL Diagnostics since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s BCAL Diagnostics with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cash Flow — BCAL Diagnostics

Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A

All Key Metrics — BCAL Diagnostics